Risk of hospitalised infection in rheumatoid arthritis patients receiving biologics following a previous infection while on treatment with anti-TNF therapy

Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial

(2013) Michael Schiff et al.   ANNALS OF THE RHEUMATIC DISEASES

Risk of infections in rheumatoid arthritis patients switching from anti-TNF agents to rituximab, abatacept, or another anti-TNF agent, a retrospective administrative claims analysis

(2013) Stephen S. Johnston et al.   SEMINARS IN ARTHRITIS AND RHEUMATISM

Difference in the risk of serious infections in patients with rheumatoid arthritis treated with adalimumab, infliximab and etanercept: results from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry

(2012) Sanne A A van Dartel et al.   ANNALS OF THE RHEUMATIC DISEASES

Lack of adverse effect of anti-tumor necrosis factor-α biologics in treatment of rheumatoid arthritis: 5 years follow-up

(2012) Ahmed M. Dewedar et al.   International Journal of Rheumatic Diseases

Use of a disease risk score to compare serious infections associated with anti-tumor necrosis factor therapy among high- versus lower-risk rheumatoid arthritis patients

(2012) Jeffrey R. Curtis et al.   ARTHRITIS CARE & RESEARCH

2012 Update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis

(2012) Jasvinder A. Singh et al.   ARTHRITIS CARE & RESEARCH

The comparative risk of serious infections among rheumatoid arthritis patients starting or switching biological agents

(2011) J. R. Curtis et al.   ANNALS OF THE RHEUMATIC DISEASES

Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient?

(2011) A. Strangfeld et al.   ANNALS OF THE RHEUMATIC DISEASES

Initiation of Tumor Necrosis Factor-α Antagonists and the Risk of Hospitalization for Infection in Patients With Autoimmune Diseases

(2011) Carlos G. Grijalva et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR)

(2009) W. G. Dixon et al.   ANNALS OF THE RHEUMATIC DISEASES

A network meta-analysis of randomized controlled trials of biologics for rheumatoid arthritis: a Cochrane overview

(2009) J. A. Singh et al.   CANADIAN MEDICAL ASSOCIATION JOURNAL

The Risk of Infections with Biologic Therapies for Rheumatoid Arthritis

(2009) Daniel E. Furst   SEMINARS IN ARTHRITIS AND RHEUMATISM

Administrative codes combined with medical records based criteria accurately identified bacterial infections among rheumatoid arthritis patients

(2008) Nivedita M. Patkar et al.   JOURNAL OF CLINICAL EPIDEMIOLOGY

Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate

(2007) M Schiff et al.   ANNALS OF THE RHEUMATIC DISEASES